	US 11,883,452 B2
	Use of combination or composition of Radix et Rhizoma Notoginseng and aspirin
Xiaobo Sun, Beijing (CN); Xiangbao Meng, Beijing (CN); Guibo Sun, Beijing (CN); and Huibo Xu, Beijing (CN)
Assigned to CHINESE ACADEMY OF MEDICAL SCIENCES INSTITUTE OF MEDICINAL PLANT DEVELOPMENT, Beijing (CN)
Appl. No. 16/650,638
Filed by CHINESE ACADEMY OF MEDICAL SCIENCES INSTITUTE OF MEDICINAL PLANT DEVELOPMENT, Beijing (CN)
PCT Filed Dec. 13, 2017, PCT No. PCT/CN2017/115813 § 371(c)(1), (2) Date Jun. 16, 2020, PCT Pub. No. WO2019/056592, PCT Pub. Date Mar. 28, 2019.
Claims priority of application No. 201710873249.7 (CN), filed on Sep. 25, 2017.
Prior Publication US 2020/0330538 A1, Oct. 22, 2020
Int. Cl. A61K 36/258 (2006.01); A61K 31/616 (2006.01)

CPC A61K 36/258 (2013.01) [A61K 31/616 (2013.01)]

11 Claims

1. A method for treatment of cardiovascular and cerebrovascular diseases, comprising administering a combination of total saponins from Radix et Rhizoma Notoginseng and aspirin to a subject in need,

wherein the total saponins from Radix et Rhizoma Notoginseng has a dose of 50 mg/kg and aspirin has a dose of 5 mg/kg; and

wherein the cardiovascular disease is selected from the group consisting of coronary heart disease, acute myocardial infarction and atherosclerotic vascular diseases; and

wherein the cerebrovascular disease is selected from the group consisting of ischemic brain stroke and thrombotic cerebrovascular disease.